Comparison of end of protocol treatment and long-term clinical outcomes for all patients undergoing endoscopic therapy for BE-related neoplasia between 2008–2010 and 2011–2013
| 2008–2010 | 2011–2013 | p Value | |
|---|---|---|---|
| CR-IM at end of protocol in all patients | 152/266 (57%) | 201/242 (83%) | <0.0001 |
| CR-IM in patients with HGD | 109/197 (55%) | 145/172 (85%) | |
| CR-IM in patients with IMC | 38/62 (61%) | 51/63 (81%) | |
| CR-IM in patients with LGD | 5/7 (71%) | 5/7 (71%) | |
| CR-D at end of protocol in all patients | 206/266 (77%) | 222/242 (92%) | <0.0001 |
| CR-D in patients with HGD | 149/197 (76%) | 159/172 (92%) | |
| CR-D in patients with IMC | 50/62 (81%) | 57/62 (92%) | |
| CR-D in patients with LGD | 7/7 (100%) | 6/7 (86%) | |
| Progression to cancer at end of protocol | 9/266 (3.4%) | 5/242 (2.1%) | 0.51 |
| Progression to cancer at most recent follow-up | 18/266 (6.7%) | 6/242 (2.5%) | Log rank 0.085 |
| Median time to most recent biopsy from first treatment for those still in follow-up (months) | 31 (3–72) n=218 | 13 (2–32) n=211 | |
| % free of dysplasia at most recent follow-up | 97% | 96% | Log rank 0.2 |
| % free of IM at most recent follow-up | 91% | 94% | Log rank 0.02 |
| Symptomatic stricture requiring endoscopic dilation | 25/266 (9.4%) | 15/242 (6.2%) | 0.18 |
CR-D, complete reversal of dysplasia; CR-IM, complete reversal of intestinal metaplasia; HGD, high-grade dysplasia; IM, intestinal metaplasia; IMC, intramucosal cancer; LGD, low-grade dysplasia; NS, not statistically significant.